動脈瘤性蜘蛛網膜下腔出血（aSAH）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 預計到2035年，法國 aSAH 市場將從約 6,000萬美元成長到 1.3億美元。
• 以下因素推動市場成長：
• 擴大先進介入神經放射學技術的應用
• 改善急性期治療及長期神經系統管理
• 市場規模的擴大是由治療頻率高和住院費用高昂所驅動的。
• 未來的成長取決於創新的神經保護療法和重症監護策略的改進。

動脈瘤性蜘蛛網膜下腔出血（aSAH）概述

動脈瘤性蜘蛛網膜下腔出血是一種危及生命的急症，由顱內動脈瘤破裂引起，導致動脈血滲漏至蛛網膜下腔，引起急性顱內高壓。典型症狀包括雷擊樣頭痛、腦膜刺激徵、畏光和意識改變。非增強CT掃描可確診，若CT未見異常，可透過腰椎穿刺檢測黃疸。嚴重程度以Hunt-Hess分級和WFNS分級進行評估。動脈瘤可透過手術夾閉或血管內栓塞術進行封閉。口服nimodipine可預防遲發性腦缺血，這是一種與血管造影術血管痙攣不同的多因子疾病。以經顱都卜勒（TCD）監測血流速度，若出現難治性缺血，則需進行誘導性高血壓治療及血管內復甦。倖存者需要復健和神經心理支持。

主要亮點

• 在德國，預計到2025年，確診的aSAH 患者人數將增加到2035年的6278 人。
• aSAH仍是一種危及生命的神經系統急症，死亡率高，且容易引發長期併發症。
• 早期發現並及時介入動脈瘤對於改善臨床療效非常重要。
• 出血後遲發性腦缺血和血管痙攣仍是主要併發症。
• 神經重症監護和血管內治療技術的進步提高了患者的存活率。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法 - 概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章 未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興治療方法。
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Outlook

Thelansis's "Global Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Aneurysmal Subarachnoid Hemorrhage treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Aneurysmal Subarachnoid Hemorrhage (aSAH) Overview

Aneurysmal Subarachnoid Hemorrhage is a life-threatening emergency caused by intracranial aneurysm rupture, releasing arterial blood into the subarachnoid space and triggering acute intracranial hypertension. Thunderclap headache, meningism, photophobia, and impaired consciousness are hallmark features. Non-contrast CT confirms diagnosis; lumbar puncture detects xanthochromia when CT is negative. Hunt-Hess and WFNS grading reflect severity. Surgical clipping or endovascular coiling secures the aneurysm. Oral nimodipine prevents delayed cerebral ischemia, a multifactorial process distinct from angiographic vasospasm. TCD surveillance monitors flow velocities; refractory ischemia warrants induced hypertension and endovascular rescue. Survivors require rehabilitation and neuropsychological support.

Key Highlights

• In Germany, the diagnosed aSAH population is projected to increase from approximately 5,883 in 2025 to 6,278 by 2035.
• aSAH remains a life-threatening neurological emergency associated with high mortality and long-term disability.
• Early aneurysm detection and rapid intervention remain essential to improving clinical outcomes.
• Delayed cerebral ischemia and vasospasm continue to represent major post-hemorrhage complications.
• Advances in neurocritical care and endovascular techniques are improving patient survival.

Market Overview

• The France aSAH market is projected to grow from approximately $60 MN to $130 MN by 2035.
• Market growth is supported by:
• Increasing utilization of advanced neurointerventional procedures
• Improved acute care and long-term neurological management
• Market value growth is driven by high treatment intensity and hospitalization costs.
• Future growth will depend on innovative neuroprotective therapies and improved critical care strategies.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)